An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

Expected or not, we believe that the news announcing that the U.S. Food and Drug Administration (FDA) approval Vertex’s (VRTX) cystic fibrosis combo product Symdeko™ (tezacaftor/ivacaftor and ivacaftor) is good news. It is indeed excellent news for the many cystic fibrosis people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis trans-membrane conductance regulator (CFTR) gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor. To be also appreciated is that Vertex is ready to launch Symdeko . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.